Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
20.80
-0.88 (-4.06%)
Mar 27, 2026, 10:13 AM EDT - Market open
Sarepta Therapeutics Employees
Sarepta Therapeutics had 835 employees as of December 31, 2025. The number of employees decreased by 537 or -39.14% compared to the previous year.
Employees
835
Change (1Y)
-537
Growth (1Y)
-39.14%
Revenue / Employee
$2,632,619
Profits / Employee
-$854,383
Market Cap
2.18B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 835 | -537 | -39.14% |
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | 743 | 244 | 48.90% |
| Dec 31, 2018 | 499 | 244 | 95.69% |
| Dec 31, 2017 | 255 | 58 | 29.44% |
| Dec 31, 2016 | 197 | -73 | -27.04% |
| Dec 31, 2015 | 270 | 66 | 32.35% |
| Dec 31, 2014 | 204 | 58 | 39.73% |
| Dec 31, 2013 | 146 | 43 | 41.75% |
| Dec 31, 2012 | 103 | 5 | 5.10% |
| Dec 31, 2011 | 98 | 0 | - |
| Dec 31, 2010 | 98 | 35 | 55.56% |
| Dec 31, 2009 | 63 | -20 | -24.10% |
| Dec 31, 2008 | 83 | -42 | -33.60% |
| Dec 31, 2007 | 125 | 8 | 6.84% |
| Dec 31, 2006 | 117 | -6 | -4.88% |
| Dec 31, 2005 | 123 | 11 | 9.82% |
| Dec 31, 2004 | 112 | 6 | 5.66% |
| Dec 31, 2003 | 106 | 17 | 19.10% |
| Dec 31, 2002 | 89 | 4 | 4.71% |
| Dec 31, 2001 | 85 | 14 | 19.72% |
| Dec 31, 2000 | 71 | 15 | 26.79% |
| Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Apellis Pharmaceuticals | 739 |
| Adaptive Biotechnologies | 624 |
| Beam Therapeutics | 511 |
| Syndax Pharmaceuticals | 298 |
| Celldex Therapeutics | 198 |
| Day One Biopharmaceuticals | 178 |
| Immunome | 177 |
| Disc Medicine | 155 |
SRPT News
- 1 day ago - Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript - Seeking Alpha
- 1 day ago - Why Is Sarepta Therapeutics Stock Exploding Today? - Benzinga
- 2 days ago - Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Business Wire
- 2 days ago - Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Business Wire
- 7 days ago - Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
- 8 days ago - Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® - Business Wire
- 11 days ago - Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Business Wire
- 23 days ago - Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha